ATP-sensitive K+ channel-deficient dilated cardiomyopathy proteome remodeled by embryonic stem cell therapy

Stem Cells

Volumn 28, Issue 8, 2010, Pages 1355-1367

  Zlatkovic Lindor, Jelena ^a   Arrell, D Kent ^a   Yamada, Satsuki ^a   Nelson, Timothy J ^a   Terzic, Andre ^a  

^a MAYO CLINIC   (United States)

Author keywords

ATP sensitive K+ channel; Bioinformatics; Dilated cardiomyopathy; Genetics; KATP channel; Networks; Protein expression; Proteomics; Regenerative medicine

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; CHAPERONE; OXIDOREDUCTASE; PROTEOME; SCAFFOLD PROTEIN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOINFORMATICS; CELL STRUCTURE; CELL THERAPY; COHORT ANALYSIS; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; EMBRYO CELL; EMBRYONIC STEM CELL; ENERGY METABOLISM; ENERGY TRANSFER; GEL ELECTROPHORESIS; GENETIC MODEL; HEART FAILURE; HEART INJURY; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE CONTRACTILITY; HEART PERFORMANCE; HEART VENTRICLE SIZE; MALE; MASS SPECTROMETRY; MOUSE; MUTANT; NONHUMAN; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN FAMILY; PROTEIN SYNTHESIS; PROTEOMICS; REGULATORY MECHANISM; STEM CELL TRANSPLANTATION; STOCHASTIC MODEL; STRESS; TWO DIMENSIONAL GEL ELECTROPHORESIS; UNINDEXED SEQUENCE;

ANIMALS; CARDIOMYOPATHY, DILATED; CELL LINE; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; EMBRYONIC STEM CELLS; FEMALE; KATP CHANNELS; MALE; MICE; STEM CELL TRANSPLANTATION; TANDEM MASS SPECTROMETRY;

EID: 77955810136     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.465     Document Type: Article

References (70)

1. Towbin JA, Bowles NE. The failing heart. Nature 2002;415:227-233.
2. Hershberger RE, Lindenfeld J, Mestroni L et al. Genetic evaluation of cardiomyopathy: A Heart Failure Society of America practice guideline. J Card Fail 2009;15:83-97.
3. Luk A, Ahn E, Soor GS et al. Dilated cardiomyopathy: A review. J Clin Pathol 2009;62:219-225.
4. Chien KR. Genomic circuits and the integrative biology of cardiac diseases. Nature 2000;407:227-232.
5. Ahmad F, Seidman JG, Seidman CE. The genetic basis for cardiac remodeling. Annu Rev Genomics Hum Genet 2005;6:185-216.
6. Olson TM. Monogenic dilated cardiomyopathy. In: Walsh RA, ed. Molecular Mechanisms of Cardiac Hypertrophy and Failure. 1st ed. Boca Raton, Florida: Taylor & Francis, 2005:525-540.
7. Hershberger RE, Cowan J, Morales A et al. Progress with genetic cardiomyopathies: Screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Heart Fail 2009;2:253-261.
8. ATP channel gating. Nat Genet 2004;36:382-387.
9. ATP channels in health and disease. J Mol Cell Cardiol 2005;38:937-943.
10. ATP channel Kir6.2 E23K variant overrepresented in human heart failure is associated with impaired exercise stress response. Hum Genet 2009;126:779-789.
11. ATP channelopathies: Diseases of metabolic homeostasis. Pflugers Arch Eur J Physiol 2010;460:295-306.
12. Ashrafian H, Watkins H. Cardiomyopathies: Therapeutics based on molecular phenotype. J Am Coll Cardiol 2007;49:1251-1264.
13. Hunt SA, Abraham WT, Chin MH et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:e391-e479.
14. Dimmeler S, Zeiher AM, Schneider MD. Unchain my heart: The scientific foundations of cardiac repair. J Clin Invest 2005;115:572-583.
15. Passier R, van Laake LW, Mummery CL. Stem cell-based therapy and lessons from the heart. Nature 2008;453:322-329.
16. Segers VF, Lee RT. Stem cell therapy for cardiac disease. Nature 2008;451:937-942. (Pubitemid 351301749)
17. Hansson EM, Lindsay ME, Chien KR. Regeneration next: Toward heart stem cell therapeutics. Cell Stem Cell 2009;5:364-377.
18. Nelson TJ, Behfar A, Yamada S et al. Stem cell platforms for regenerative medicine. Clin Transl Sci 2009;2:222-227.
19. Anversa P, Kajstura J, Leri A et al. Life and death of cardiac stem cells: A paradigm shift in cardiac biology. Circulation 2006;113:1451-1463.
20. Torella D, Ellison GM, Méndez-Ferrer S et al. Resident human cardiac stem cells: Role in cardiac cellular homeostasis and potential for myocardial regeneration. Nat Clin Pract Cardiovasc Med 2006;3(suppl 1):8-13.
21. Kajstura J, Hosoda T, Bearzi C et al. The human heart: A self-renewing organ. Clin Transl Sci 2008;1:80-86.
22. Bergmann O, Bhardwaj RD, Bernard S et al. Evidence for cardiomyocyte renewal in humans. Science 2009;324:98-102.
23. De Angelis A, Piegari E, Cappetta D et al. Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation 2010;121:276-292.
24. Yamada S, Nelson TJ, Crespo-Diaz RJ et al. Embryonic stem cell therapy of heart failure in genetic cardiomyopathy. Stem Cells 2008;26:2644-2653.
25. Hodgson DM, Behfar A, Zingman LV et al. Stable benefit of embryonic stem cell therapy in myocardial infarction. Am J Physiol Heart Circ Physiol 2004;287:H471-H479.
26. Ménard C, Hagège AA, Agbulut O et al. Transplantation of cardiac-committed mouse embryonic stem cells to infarcted sheep myocardium: A preclinical study. Lancet 2005;366:1005-1012.
27. Kolossov E, Bostani T, Roell W et al. Engraftment of engineered ES cell-derived cardiomyocytes but not BM cells restores contractile function to the infarcted myocardium. J Exp Med 2006;203:2315-2327.
28. Chung S, Dzeja PP, Faustino RS et al. Mitochondrial oxidative metabolism is required for the cardiac differentiation of stem cells. Nat Clin Pract Cardiovasc Med 2007;4(suppl 1):60-67.
29. Laflamme MA, Chen KY, Naumova AV et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol 2007;25:1015-1024.
30. Kehat I, Khimovich L, Caspi O et al. Electromechanical integration of cardiomyocytes derived from human embryonic stem cells. Nat Biotechnol 2004;22:1282-1289. (Pubitemid 39341201)
31. Baba S, Heike T, Yoshimoto M et al. Flk1+ cardiac stem/progenitor cells derived from embryonic stem cells improve cardiac function in a dilated cardiomyopathy mouse model. Cardiovasc Res 2007;76:119-131. (Pubitemid 47362035)
32. Behfar A, Perez-Terzic C, Faustino RS et al. Cardiopoietic programming of embryonic stem cells for tumor-free heart repair. J Exp Med 2007;204:405-420.
33. Nelson TJ, Martinez-Fernandez A, Yamada S et al. Repair of acute myocardial infarction with human stemness factors induced pluirpotent stem cells. Circulation 2009;120:408-416.
34. Barabási AL, Oltvai ZN. Network biology: Understanding the cell's functional organization. Nat Rev Genet 2004;5:101-113.
35. Weston AD, Hood L. Systems biology, proteomics, and the future of health care: Toward predictive, preventative, and personalized medicine. J Proteome Res 2004;3:179-196. (Pubitemid 38500984)
36. Arrell DK, Niederländer NJ, Faustino RS et al. Cardioinductive network guiding stem cell differentiation revealed by proteomic cartography of tumor necrosis factor α-primed endodermal secretome. Stem Cells 2008;26:387-400.
37. Van Hoof D, Heck AJ, Krijgsveld J et al. Proteomics and human embryonic stem cells. Stem Cell Res 2008;1:169-182.
38. + channel knockout induces cardiac proteome remodeling predictive of heart disease susceptibility. J Proteome Res 2009;8:4823-4834.
39. ATP channel causes maladaptive remodeling and heart failure in hypertension. Hum Mol Genet 2006;15:2285-2297.
40. + channels in pressure overload-induced congestive heart failure revealed in KCNJ11 Kir6.2-null mutant. J Physiol 2006;577:1053-1065.
41. Martinez-Fernandez A, Nelson TJ, Yamada S et al. iPS programmed without c-MYC yield proficient cardiogenesis for functional heart chimerism. Circ Res 2009;105:648-656.
42. Yamada S, Nelson TJ, Behfar A et al. Stem cell transplant into preimplantation embryo yields myocardial infarction-resistant adult phenotype. Stem Cells 2009;27:1697-1705.
43. ATP channel-deficient hypertensive heart maps risk for maladaptive cardiomyopathic outcome. Proteomics 2009;9:1314-1325.
44. Arrell DK, Niederländer NJ, Perez-Terzic C et al. Embryonic stem cell cardiac differentiation: A proteomic perspective. Adv Mol Med 2006;2:149-156.
45. Arrell DK, Niederländer NJ, Perez-Terzic C et al. Pharmacoproteomics: Advancing the efficacy and safety of regenerative therapeutics. Clin Pharmacol Ther 2007;82:316-319.
46. Perkins DN, Pappin DJC, Creasy DM et al. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 1999;20:3551-3567.
47. Link AJ, Eng J, Schieltz DM et al. Direct analysis of protein complexes using mass spectrometry. Nat Biotechnol 1999;17:676-682. (Pubitemid 29316146)
48. Cline MS, Smoot M, Cerami E et al. Integration of biological networks and gene expression data using Cytoscape. Nat Protoc 2007;2:2366-2382.
49. Assenov Y, Ramírez F, Schelhorn S-E et al. Computing topological parameters of biological networks. Bioinformatics 2008;24:282-284.
50. Barabasí A-L, Albert R. Emergence of scaling in random networks. Science 1999;286:509-512.
51. Jeong H, Tombor B, Albert R et al. The large-scale organization of metabolic networks. Nature 2000;407:651-654.
52. Newman MEJ. The structure and function of complex networks. SIAM Rev 2003;45:167-256.
53. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008;358:2148-2159.
54. Bell J. Predicting disease using genomics. Nature 2004;429:453-456.
55. Arab S, Gramolini AO, Ping P et al. Cardiovascular proteomics: Tools to develop novel biomarkers and potential applications. J Am Coll Cardiol 2006;48:1733-1741.
56. Asakura M, Kitakaze M. Global gene expression profiling in the failing myocardium. Circ J 2009;73:1568-1576.
57. Gstaiger M, Aebersold R. Applying mass spectrometry-based proteomics to genetics, genomics and network biology. Nat Rev Genet 2009;10:617-627.
58. Merico D, Gfeller D, Bader GD. How to visually interpret biological data using networks. Nat Biotechnol 2009;27:921-924.
59. Arrell DK, Terzic A. Network systems biology for drug discovery. Clin Pharmacol Ther 2010;88:120-125.
60. Chien KR. Stress pathways and heart failure. Cell 1999;98:555-558.
61. Dzeja PP, Redfield MM, Burnett JC et al. Failing energetics in failing hearts. Curr Cardiol Rep 2000;2:212-217.
62. Neubauer S. The failing heart: An engine out of fuel. N Engl J Med 2007;356:1140-1151.
63. Chen CH, Budas GR, Churchill EN et al. Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science 2008;321:1493-1495.
64. Ping P. Getting to the heart of proteomics. N Engl J Med 2009;360:532-534.
65. Waldman SA, Terzic A. Therapeutic targeting: A crucible for individualized medicine. Clin Pharmacol Ther 2008;83:651-654. (Pubitemid 351556027)
66. 3" regenerative medicine paradigm. Clin Transl Sci 2008;1:168-171.
67. Lusis AJ, Weiss JN. Cardiovascular networks. Systems-based approaches to cardiovascular disease. Circulation 2010;121:157-170.
68. Yildirim MA, Goh KI, Cusick ME et al. Drug-target network. Nat Biotechnol 2007;25:1119-1126.
69. Hood L, Heath JR, Phelps ME et al. Systems biology and new technologies enable predictive and preventative medicine. Science 2004;306:640-643. (Pubitemid 39440903)
70. Gersh BJ, Simari RD, Behfar A et al. Cardiac cell repair therapy: A clinical perspective. Mayo Clin Proc 2009;84:876-892.